Med24
metabolic-therapy 27. 10. 2026 • 2 min read • Clinical gastroenterology and hepatology : the official clinical practice journal of the American Ga

High burden of potentially undiagnosed MASH in a general population in Sweden.

BACKGROUND AND AIMS: Few studies have explored the prevalence and outcomes of fibrotic metabolic dysfunction-associated steatohepatitis (MASH) in the general population. We aimed to characterize patients at risk of MASH using the validated Fibrotic NASH Index (FNI) and to compare the incidence of major adverse liver...

High burden of potentially undiagnosed MASH in a general population in Sweden.

This study investigated the prevalence of potentially undiagnosed fibrotic metabolic dysfunction-associated steatohepatitis (MASH) within a general population. The aim was to characterize individuals at risk of MASH using the Fibrotic NASH Index (FNI) and to compare outcomes between risk groups and those with established MASH.

Patient Data and Risk Stratification

Data was collected from patients in Stockholm, Sweden, between 2010 and 2020, and from specialist care records between 1998 and 2022. Patients were classified as high risk based on FNI scores and the presence of cardiometabolic risk factors, and low risk based on FNI scores without these factors. Individuals with established MASH were identified by ICD-10 code (K75.8).

Sponsored content

Key Clinical Findings

Analysis of FNI data revealed that 23% of patients were considered high risk and 39% were considered low risk. Among patients with established MASH, major adverse liver outcomes (MALO) were more common than in high-risk FNI patients. The rate of incident MALO was higher in diagnosed MASH patients compared to the high-risk FNI group. The rate of major adverse cardiovascular events (MACE) was also higher in high-risk FNI patients compared to low-risk FNI patients. The study highlighted a significant burden of potentially undiagnosed at-risk MASH within the population. Almost half of patients with established MASH already exhibited MALO at baseline, emphasizing the importance of earlier diagnosis.

Original Scientific Source
Clinical gastroenterology and hepatology : the official clinical practice journal of the American Ga
View Original Source
Medical Disclaimer All calculations, recommendations, and interpretations provided by this tool are for informational and educational purposes only. They do not substitute professional medical advice, diagnosis, or treatment. Always consult your physician regarding any health concerns.

Recommended Medical News

All news →
Nanotechnology-Driven 18F-FDG Imaging to Understand the Change in Insulin Sensitivity: Current Evidence, Methodological Gaps, and Translational Challenges.
metabolic-therapy

Nanotechnology-Driven 18F-FDG Imaging to Understand the Change in Insulin Sensitivity: Current Evidence, Methodological Gaps, and Translational Challenges.

Insulin resistance is an important metabolic derangement contributing to the pathogenesis of type 2 diabetes, obesity, metabolic syndrome, and other chronic diseases, underlining the requirement for techniques that enable in vivo analysis of tissue-specific glucose metabolism. 18F-fluorodeoxyglucose positron emission...

10. 11. 2026 Read article →
Cardiometabolic Abnormalities among Normal-Weight Adults: Prevalence and Associated Sociodemographic and Lifestyle Factors in a Large Spanish Cohort.
metabolic-therapy

Cardiometabolic Abnormalities among Normal-Weight Adults: Prevalence and Associated Sociodemographic and Lifestyle Factors in a Large Spanish Cohort.

BACKGROUND: Although body mass index (BMI) is widely used to assess obesity-related health risks, it may fail to detect individuals with normal weight who present with significant cardiometabolic abnormalities. This phenotype, often overlooked in clinical practice, is associated with increased risk of cardiovascular...

30. 10. 2026 Read article →
Advertisement